February 6, 2023
Via: Biopharm InternationalThermo Fisher Scientific recently announced that it had become a founding sponsor of Momentum Labs, a collaborative laboratory and office space to be located in Alachua, Fla. The venture, spearheaded by Gainesville real estate development firm Concept Companies, is designed […]
January 27, 2023
Via: PharmaphorumWhile global macroeconomic uncertainty continues to impact financing, the pharma industry has focused on UK biotechs to strengthen product pipelines. But with difficult public markets and low investor appetite, new launches were almost unseen in 2022, with public markets contributing […]
January 25, 2023
Via: Biopharma DiveGoulburn, Dar and Li believe a shift is underway in biotech. The three friends, who have helped build new companies with their respective firms for about a decade, are convinced the search for new drugs is becoming increasingly digitized. Artificial […]
January 10, 2023
Via: Biopharma DiveHere are five top questions facing emerging biotech companies this year: Will the IPO market open back up? The big question facing investors is whether the biotech industry will see the kind of boom it experienced in 2020 and 2021. […]
January 5, 2023
Via: PharmaphorumFor biotech to achieve our societal goals, we need to build up the foundational systems that support modern science. Government investment will be critical. Technological resources will also be instrumental — from overcoming current technical skills gaps to modernising how […]
January 4, 2023
Via: PharmaphorumThe intention is to streamline the process for patients wishing to access their medical records via electronic health record systems (“EHR systems”) and to facilitate the ability for researchers, innovators, and policy makers to use the data in a trusted […]
Clinical Trials, Research and Development
January 3, 2023
Via: Biopharma DiveThe biotechnology industry begins 2023 at a crossroads. In many ways, the sector is coming off of one of its toughest years in recent memory. Initial public offerings ground to a halt. A widely followed biotech stock index plunged nearly […]
November 15, 2022
Via: Biopharma DiveTwo months ago, biotechnology startup Good Therapeutics struck it big. A cancer immunotherapy the company was working on drew such interest from Roche that the Swiss pharmaceutical giant paid $250 million, far more than the $30 million the startup had […]
November 10, 2022
Via: PharmaphorumThe merger will create a clinical-stage cancer-focused biotech with funding that will last into 2024 and pipeline headed by ATX-101, a peptide-targeting PCNA being developed by APIM in clinical trials for platinum-sensitive ovarian cancer and sarcoma. Nordic Nanovector was hit […]
October 20, 2022
Via: Biopharma DivePlunging stock prices shook the biotech sector this year. Young companies attempting to go public found little appetite for the sky-high valuations that were common in 2020 and 2021’s bull run of IPOs. Some investors described that period as resulting […]
October 6, 2022
Via: Biopharma DiveScientists knew the gene all too well. Decades of research had shown that mutated versions of it were behind a variety of cancers. But designing a medicine that could block the effects of this gene, called KRAS, proved exceptionally challenging, […]
October 3, 2022
Via: Biopharma DiveAstraZeneca’s rare disease unit Alexion will acquire gene editing specialist LogicBio Therapeutics in a small buyout deal, the companies announced Monday. Under the terms of the agreement, Alexion will acquire all of LogicBio’s outstanding shares for $2.07 each, representing a […]
September 26, 2022
Via: Biopharma DivePrime’s filing represents a key test for biotech initial public offerings, which are showing some early signs of life after a prolonged slowdown. Twelve days ago, autoimmune drug developer Third Harmonic Bio provided the sector with a lift. By raising […]
September 15, 2022
Via: GENThis week has been one of the most exciting that the biotechnology community has seen for some time. Plans that have been in the making for a decade are finally being brought to fruition by actions taken by the Biden […]
September 6, 2022
Via: Contract PharmaAptar Pharma, a leader in drug delivery and active material science solutions and services, has acquired Metaphase Design Group Inc., a leader in applying the science of human factors engineering and ergonomics to product design. The acquisition expands Aptar Pharma’s […]
September 2, 2022
Via: PharmaphorumThe $20-per-share agreement was a premium of 92% over Forma’s closing share price yesterday, but its stock leaped after the deal was announced from $13.40 to just under the deal price. The biotech went public via a $278 million IPO […]
Manufacturing, Research and Development
September 2, 2022
Via: Biopharm InternationalWith biosimilars entering the market, and more expected to reach the market in the near future, the need for good manufacturing practice (GMP) compliance is growing more crucial for bulk monoclonal antibody (mAb) manufacturing. Beyond innovator biologics, biosimilars are expected […]
Cell and Gene Therapy, Industry
September 1, 2022
Via: Biopharma DiveSangamo Therapeutics is continuing to enroll and treat patients with a rare genetic condition called Fabry disease in an early clinical trial of a gene therapy it is developing, announcing Tuesday updated results from the first 11 study participants. Data […]
September 1, 2022
Via: Contract PharmaOri Biotech Ltd., a leader in cell and gene therapy (CGT) manufacturing technology, has shared details of its strategic expansion plan following its $100 million Series B funding round in January 2022, including adding key expertise and personnel and new […]
Cell and Gene Therapy, Industry
August 31, 2022
Via: Biopharma DiveFDA officials are proceeding with caution as the gene editing field advances. In another recent example, the agency had issued a partial clinical hold to Editas Medicine before this July allowing that company to proceed with testing of a sickle […]